187 related articles for article (PubMed ID: 17990141)
21. [Successful treatment of idiopathic acquired refractory thrombotic thrombocytopenic purpura with an association of rituximab-vindesine. Report of one case].
Ojeda-Uribe M; Brunot A; Issler M
Rev Med Chil; 2005 Nov; 133(11):1349-54. PubMed ID: 16446859
[TBL] [Abstract][Full Text] [Related]
22. Rituximab and intermediate-purity plasma-derived factor VIII concentrate (Koate®) as adjuncts to therapeutic plasma exchange for thrombotic thrombocytopenic purpura in patients with an ADAMTS13 inhibitor.
Pandey S; Nakagawa M; Rosenbaum ER; Arnaoutakis K; Hutchins LF; Makhoul I; Milojkovic N; Cottler-Fox M
J Clin Apher; 2015 Feb; 30(1):50-4. PubMed ID: 25042026
[TBL] [Abstract][Full Text] [Related]
23. Rituximab provided long-term remission in a patient with refractory relapsing thrombotic thrombocytopenic purpura.
Kosugi S; Matsumoto M; Ohtani Y; Take H; Ishizashi H; Fujimura Y; Kuyama J
Int J Hematol; 2005 Jun; 81(5):433-6. PubMed ID: 16158827
[TBL] [Abstract][Full Text] [Related]
24. Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report.
Galbusera M; Bresin E; Noris M; Gastoldi S; Belotti D; Capoferri C; Daina E; Perseghin P; Scheiflinger F; Fakhouri F; Grünfeld JP; Pogliani E; Remuzzi G
Blood; 2005 Aug; 106(3):925-8. PubMed ID: 15827129
[TBL] [Abstract][Full Text] [Related]
25. Rituximab therapy for refractory thrombotic thrombocytopenic purpura.
Gutterman LA; Kloster B; Tsai HM
Blood Cells Mol Dis; 2002; 28(3):385-91. PubMed ID: 12367582
[TBL] [Abstract][Full Text] [Related]
26. Two cases of refractory thrombotic thrombocytopenic purpura associated with collagen vascular disease were significantly improved by rituximab treatment.
Kameda T; Dobashi H; Kittaka K; Susaki K; Yamaoka G; Arai K; Tokuda M; Ishida T
Clin Rheumatol; 2007 Dec; 26(12):2159-2162. PubMed ID: 17562094
[TBL] [Abstract][Full Text] [Related]
27. Rituximab as preventive therapy of a clinical relapse in TTP with ADAMTS13 inhibitor.
Schleinitz N; Ebbo M; Mazodier K; Poullin P; Bernit E; Veit V; Veyradier A; Fakhouri F; Kaplanski G; Harle JR
Am J Hematol; 2007 May; 82(5):417-8. PubMed ID: 17266057
[No Abstract] [Full Text] [Related]
28. Targeting the inhibitor of ADAMTS13 in thrombotic thrombocytopenic purpura.
Cataland SR; Wu HM
Expert Opin Pharmacother; 2007 Mar; 8(4):437-44. PubMed ID: 17309338
[TBL] [Abstract][Full Text] [Related]
29. Current management and therapeutical perspectives in thrombotic thrombocytopenic purpura.
Coppo P; Veyradier A
Presse Med; 2012 Mar; 41(3 Pt 2):e163-76. PubMed ID: 22265954
[TBL] [Abstract][Full Text] [Related]
30. Acquired, noncongenital thrombotic thrombocytopenic purpura in children and adolescents: clinical management and the use of ADAMTS 13 assays.
McDonald V; Liesner R; Grainger J; Gattens M; Machin SJ; Scully M
Blood Coagul Fibrinolysis; 2010 Apr; 21(3):245-50. PubMed ID: 20083997
[TBL] [Abstract][Full Text] [Related]
31. [Acquired idiopathic thrombotic thrombocytopenic purpura: arguments for an autoimmune disease].
Coppo P; Veyradier A; Monge M;
Presse Med; 2006 Dec; 35(12 Pt 2):1876-86. PubMed ID: 17159713
[TBL] [Abstract][Full Text] [Related]
32. Rituximab in the treatment of TTP.
Scully M
Hematology; 2012 Apr; 17 Suppl 1():S22-4. PubMed ID: 22507771
[TBL] [Abstract][Full Text] [Related]
33. Thrombotic thrombocytopenic purpura: from diagnosis to therapy.
Mariotte E; Veyradier A
Curr Opin Crit Care; 2015 Dec; 21(6):593-601. PubMed ID: 26418759
[TBL] [Abstract][Full Text] [Related]
34. Bortezomib for chronic relapsing thrombotic thrombocytopenic purpura: a case report.
Yates S; Matevosyan K; Rutherford C; Shen YM; Sarode R
Transfusion; 2014 Aug; 54(8):2064-7. PubMed ID: 24655327
[TBL] [Abstract][Full Text] [Related]
35. Rituximab was effective on refractory thrombotic thrombocytopenic purpura but induced a flare of hemophagocytic syndrome in a patient with systemic lupus erythematosus.
Kamiya K; Kurasawa K; Arai S; Maezawa R; Hanaoka R; Kumano K; Fukuda T
Mod Rheumatol; 2010 Feb; 20(1):81-5. PubMed ID: 19784542
[TBL] [Abstract][Full Text] [Related]
36. Summaries for patients. Treatment of refractory thrombotic thrombocytopenic purpura.
Ann Intern Med; 2003 Jan; 138(2):I38. PubMed ID: 12529111
[No Abstract] [Full Text] [Related]
37. Recurrent thrombotic thrombocytopenic purpura treated repeatedly and successfully with the monoclonal antibody rituximab.
Herbei L; Venugopal P
Clin Adv Hematol Oncol; 2006 Mar; 4(3):215-7; discussion 217-8. PubMed ID: 16728931
[No Abstract] [Full Text] [Related]
38. Response to rituximab in a refractory case of thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus.
Niaz FA; Aleem A
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):109-12. PubMed ID: 20061703
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: results of a Spanish multicenter study.
Rubia J; Moscardó F; Gómez MJ; Guardia R; Rodríguez P; Sebrango A; Zamora C; Debén G; Goterris R; López R; Peña F; Pujol M; Vidaller A; Río-Garma JD; Sanz MA;
Transfus Apher Sci; 2010 Dec; 43(3):299-303. PubMed ID: 20934383
[TBL] [Abstract][Full Text] [Related]
40. Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse.
Westwood JP; Webster H; McGuckin S; McDonald V; Machin SJ; Scully M
J Thromb Haemost; 2013 Mar; 11(3):481-90. PubMed ID: 23279219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
